Condition-Specific Health
GLP-1 Agonists Linked to Lower Alcohol Hospitalization Risk
A target trial emulation study spanning multiple health systems found consistent associations between GLP-1 receptor ag…
Condition-Specific Health 89 stories
Condition-Specific Health
ALPCO Adds H. pylori, Lactoferrin Assays to KleeYa® GI Test Menu
ALPCO, part of NuvinkaDx, has secured Health Canada licenses for two stool-based immunoassays that support gut-health a…
Condition-Specific Health
Noom's 'Lose for Keeps' Campaign Pairs GLP-1s With Behavior Change
Noom's new integrated brand campaign positions behavior change as the essential complement to GLP-1 therapy, entering a…
Condition-Specific Health
Kashi Gut Health Granola Combines Prebiotics and Live Cultures
Kashi's new granola delivers prebiotic chicory root fiber alongside gut-activated cultures, positioning the WK Kellogg …
Condition-Specific Health
WonderLab's GOLDGUT-M520 Probiotic Strain Anchors Immunity Campaign
WonderLab's consumer-facing science series positions GOLDGUT-M520 at the intersection of gut microbiome research and in…
Condition-Specific Health
Lifeway Kefir Marks 40 Years with SoHo Pop-Up on National Kefir Day
The Nasdaq-listed kefir pioneer uses experiential retail to drive category awareness as fermented dairy's probiotic cre…
Condition-Specific Health
Peanuts Linked to Brain Health Benefits via Nutrient Density
As the cognitive-wellness category accelerates, operators are eyeing whole-food ingredients with established safety pro…
Condition-Specific Health
Rivox Labs Debuts Nicotine-Free Focus Pouches and Energy Gum
The nicotine-free oral delivery format is gaining traction as a disruptive vector for nootropic and energy ingredients …
Condition-Specific Health
Cardiawave Launches Valvosoft Treatments Post-CE Mark Approval
The CE Mark clearance positions Valvosoft within Europe's growing cardiac therapeutics market as the company accelerate…
Condition-Specific Health
ProSomnus, MonitAir Link OAT Device Data to Remote OSA Monitoring
The collaboration targets care-gap closure in OSA management, a condition increasingly addressed by sleep-support nutra…
Condition-Specific Health
XBiotech's Vilamakitug Enters Phase II Trial for Axial SpA
The IND application completed its 30-day FDA review without a clinical hold, opening U.S. patient enrollment for the an…
Condition-Specific Health
XBiotech's Vilamakitug Clears FDA IND Review for Phase II Axial SpA Trial
The 30-day FDA review with no clinical hold signals a clear regulatory path forward for the IL-1α–targeting monoclonal …